PT  - JOURNAL ARTICLE
AU  - Packer, R
AU  - Williams, AT
AU  - Hennah, W
AU  - Eisenberg, MT
AU  - Fawcett, KA
AU  - Pearson, W
AU  - Guyatt, A
AU  - Edris, A
AU  - Hollox, EJ
AU  - Rao, BS
AU  - Bratty, JR
AU  - Wain, LV
AU  - Dudbridge, F
AU  - Tobin, MD
TI  - DeepPheWAS: an R package for phenotype generation and association analysis for phenome-wide association studies
AID  - 10.1101/2022.05.05.22274419
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.05.22274419
4099  - http://medrxiv.org/content/early/2022/08/13/2022.05.05.22274419.short
4100  - http://medrxiv.org/content/early/2022/08/13/2022.05.05.22274419.full
AB  - Summary DeepPheWAS is an R package for phenome wide association studies that creates clinically-curated composite phenotypes, and integrates quantitative phenotypes from primary care data, longitudinal trajectories of quantitative measures, disease progression, and drug response phenotypes. Tools are provided for efficient analysis of association with any genetic input, under any genetic model, with optional sex-stratified analysis, and for developing novel phenotypes.Availability and Implementation The DeepPheWAS R package is freely available under GNU general public licence v3.0 from at https://github.com/Richard-Packer/DeepPheWAS.Contact richard.packer{at}leicester.ac.ukSupplementary information Supplementary methods and results are available at Bioinformatics online.Competing Interest StatementMDT, RP, ATW, FD and LVW received funding from Orion Pharma within the scope of the submitted work, and from GSK for collaborative research projects outside of the submitted work . WH, BSR, MM, and RB are salaried employees of Orion Pharma within the scope of the submitted work.Funding StatementThis work is supported by: Orion Pharma funded a research collaboration with the University of Leicester, which supported the development of Deep-PheWAS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank had obtained ethics approval from the North West Multi-centre Research Ethics Committee which covers the UK (approval number: 11/NW/0382) and had obtained informed consent from all participants. The UK Biobank approved an application for use of the data (ID 43027).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is available on application to UK Biobank. Scripts to produce the results highlighted here are availble from provided github address. https://github.com/Richard-Packer/Deep-PheWAS